本报北京10月12日电 （记者林丽鹂）市场监管总局发布数据：前三季度，我国新批准发布国家标准物 质891项，同比增长75.7%。其中，国家一级标准物质48项，占比5.4%，同比增长23.1%；国家二级标准 物质843项，占比94.6%，同比增长80.1%。 标准物质是开展化学、生物等检测活动必不可少的"标尺"和"砝码"，是国家计量能力建设的关键要素。 截至目前，市场监管总局已累计批准发布19349项国家标准物质。 《 人民日报 》（ 2025年10月13日 01 版） (责编：赵欣悦、袁勃) 关注公众号：人民网财经 ...

标准物质是开展化学、生物等检测活动必不可少的"标尺"和"砝码"，是国家计量能力建设的关键要素。 截至目前，市场监管总局已累计批准发布19349项国家标准物质。 本报北京10月12日电 （记者林丽鹂）市场监管总局发布数据：前三季度，我国新批准发布国家标准物 质891项，同比增长75.7%。其中，国家一级标准物质48项，占比5.4%，同比增长23.1%；国家二级标准 物质843项，占比94.6%，同比增长80.1%。 （文章来源：人民日报） ...

记者今天了解到，据市场监管总局统计，前三季度，我国新批准发布国家标准物质891项，同比增 长75.7%。国家标准物质批准发布数量实现快速增长，主要是由于经营主体通过提升标准物质研制生产 能力，逐步建立快速响应市场需求机制，成为国家标准物质高质量发展的核心动力。 前三季度批准发布企业申报标准物质655项，占比73.5%，同比增长93.2%，全部为国家二级标准物 质；批准发布科研事业单位申报标准物质236项，占比26.5%，同比增长47.8%，其中国家一级标准物质 占比20.7%。从标准物质批准发布数量来看，企业在标准物质研制生产环节仍稳居主体地位，标准物质 研制生产企业紧扣市场需求，为满足产业精准测试需求作出突出贡献。科研事业单位更加注重高端技术 需求，研制生产的国家一级标准物质技术指标达到国内领先、国际先进水平。 截至目前，市场监管总局已累计批准发布19349项国家标准物质，标准物质国际计量互认能力稳居 国际第一梯队。(记者 李晶晶) 从增长领域看，前三季度，我国批准发布环境监测领域标准物质353项，占比39.6%，同比增长 100.6%，均为国家二级标准物质，增长较快，但仍需"提质进阶"。 前三季度批准发布 ...

企业保量，科研提质，标准物质研制生产呈现互补格局。1—7月企业研制生产标准物质401项，占比 73%，同比增长68.5%，均为国家二级标准物质；科研事业单位研制生产标准物质148项，占比27%，同 比增长29.8%，其中国家一级标准物质31项、二级标准物质117项。科研事业单位聚焦科技研发高端测 量需求，国家一级标准物质研制生产主体均为科研事业单位，技术指标达到国内甚至国际先进水平。 本报北京8月8日电(记者孔德晨)近日，国家市场监督管理总局发布数据，截至目前已累计批准发布国家 标准物质19007项，我国标准物质国际计量互认能力稳居全球第一梯队。1—7月新批准发布国家标准物 质549项，同比增长56%，标准物质研制生产供需两旺。 传统领域是标准物质的"基本盘"。以环境监测为例，1—7月批准发布标准物质205项，占比37.3%，同比 增长64%。在高端生物医药、新型半导体制造等新兴领域，标准物质研制生产仍处在"量质爬升"阶段， 但能够解决产业发展的关键计量技术难题。 ...

本文由 AI 算法生成，仅作参考，不涉投资建议，使用风险自担 【市场监管总局：我国标准物质国际计量互认能力居全球第一梯队】近日，市场监管总局公布数据，截 至目前累计批准发布国家标准物质19007项，我国标准物质国际计量互认能力稳居全球第一梯队。1 - 7 月新批准发布549项，同比增长56%，研制生产供需两旺。 标准物质应用领域双轮驱动，传统依然 是"基本盘"。1 - 7月环境监测领域批准发布205项，占比37.3%，同比增长64%。新兴领域虽处"量质爬 升"阶段，但能解决关键计量技术难题，如"突变MSTN基因产量性状改良肉牛质粒DNA标准物质"等。 研制生产呈现企业与科研互补格局。1 - 7月企业研制401项，占比73%，同比增68.5%，均为国家二级； 科研单位研制148项，占比27%，同比增29.8%，含一级31项、二级117项，聚焦高端测量需求。 华北地 区集中度高，显现集群效应。1 - 7月批准发布244项，占比44.4%，同比增165.2%。北京数量居前，形成 区域特色。科研单位和企业数量相当，立足优势提升质与量。 市场监管总局将加强能力建设，推动相 关标准物质研制生产，为高质量发展提供计量支撑。 ...

【市场监管总局：我国标准物质国际计量互认能力居全球第一梯队】近日，市场监管总局公布数据，截 至目前，累计批准发布国家标准物质19007项，我国标准物质国际计量互认能力稳居全球第一梯队。1 - 7月新批准发布549项，同比增长56%，研制生产供需两旺。 标准物质应用领域双轮驱动，传统领域 是"基本盘"。1 - 7月环境监测领域批准发布205项，占比37.3%，同比增64%。新兴领域虽处"量质爬 升"阶段，但能解决关键计量技术难题，如相关标准物质用于肉牛育种、半导体开发。 标准物质研制生 产呈现互补格局。1 - 7月企业研制生产401项，占比73%，同比增68.5%；科研事业单位研制生产148 项，占比27%，同比增29.8%。科研事业单位聚焦高端测量需求，是国家一级标准物质研制主体。 华北 地区标准物质研制生产集中度高，初步显集群效应。1 - 7月批准发布244项，占比44.4%，同比增 165.2%。北京数量居前，形成区域特色，科研事业单位和企业立足优势提升质与量。 市场监管总局将 加强国家标准物质能力建设，推动相关研制生产，为社会高质量发展提供计量支撑。 本文由 AI 算法生成，仅作参考，不涉投资建议，使用 ...

Core Insights - In the first half of this year, China approved the establishment of 524 national standard materials, representing a year-on-year increase of 78.8% [1] - The total number of approved national standard materials has reached 18,982, with the country maintaining a leading position in international measurement mutual recognition capabilities [1] Group 1: National Standard Materials Overview - National first-level standard materials accounted for 5.9% of the total, with 31 items approved, showing a year-on-year growth of 47.6% [1] - National second-level standard materials made up 94.1% of the total, with 493 items approved, reflecting a year-on-year increase of 81.3% [1] Group 2: Application Areas - In the environmental monitoring sector, 202 standard materials were approved, accounting for 38.6% of the total, with a year-on-year growth of 69.7% [2] - The manufacturing and petrochemical industries saw the approval of 150 standard materials, representing 28.6% of the total, with a significant year-on-year increase of 108.3% [2] - In the food and agricultural product safety testing sector, 134 standard materials were approved, making up 25.6% of the total, with a year-on-year growth of 78.6% [2] - The medical and health sector had 38 standard materials approved, accounting for 7.2% of the total, with a year-on-year increase of 40.7% [2] Group 3: Specific Developments - The newly approved EGFR gene mutation genomic DNA standard material is expected to enhance the quality of companion diagnostics for targeted therapy in non-small cell lung cancer, thereby improving treatment outcomes [1] - The newly established series of graphite physical property standard materials will provide precise and reliable testing benchmarks for lithium battery manufacturers, supporting raw material quality control and production process optimization [2]

导读： 1—6月，我国新批准建立国家标准物质524项，同比增长78.8%，涉及研制单位51家。截至目前，市场监管总局累计批准建立国家标准物质18982项，标 准物质国际计量互认能力稳居国际第一梯队。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 从研制单位类型看， 企业申报标准物质379项，占比72.3%，同比增长86.7%；科研事业单位申报145项，占比27.7%，同比增长61.1%。 企业和科研事业单位新建标准物质总数均有大幅度增长，标准物质研制单位以企业为主，标准物质行业经济活力回暖加速。 从地域分布看， 华北地区新建标准物质234项，占比44.7%;华东地区新建标准物质124项，占比23.7%；东北地区新建标准物质62项，占比 11.8%;西北地区新建标准物质48项，占比9.2%；华南地区新建标准物质32项，占比6.1%;西南地区新建标准物质24项，占比4.5%；华中 地区未新建标准物质。华北地区新建标准物质数量最多，西南地区新建标准物质增速较低。 标准物质是开展化学、生物等检测活动必不可少的"标尺"和"砝码"。截至目前，市场监管 ...

Core Insights - In the first half of this year, China approved 524 new national standard substances, marking a significant year-on-year increase of 78.8% [1] - The increase in approved standard substances indicates a recovery in industry vitality, with enterprises leading the submissions [1] Summary by Category Approval Statistics - A total of 524 national standard substances were approved, with 31 classified as national first-level standards (5.9% of total) and 493 as national second-level standards (94.1% of total) [1] - The first-level standards saw a year-on-year increase of 47.6%, while the second-level standards increased by 81.3% [1] Application Fields - Environmental monitoring received the highest number of approvals with 202 items (38.6% of total), reflecting a year-on-year increase of 69.7% [1] - The manufacturing and petrochemical industries accounted for 150 items (28.6% of total), with a substantial increase of 108.3% [1] - Food and agricultural product safety testing had 134 items (25.6% of total), increasing by 78.6% [1] - The medical and health sector received 38 items (7.2% of total), with a growth of 40.7% [1] Submissions by Type - Enterprises submitted 379 items (72.3% of total), showing an increase of 86.7% year-on-year [1] - Research institutions submitted 145 items (27.7% of total), with a year-on-year increase of 61.1% [1] Regional Distribution - The North China region led with 234 items (44.7% of total), followed by East China with 124 items (23.7%) [1] - Northeast China approved 62 items (11.8%), Northwest China 48 items (9.2%), South China 32 items (6.1%), Southwest China 24 items (4.5%), and Central China had no new approvals [1] - The North China region had the highest number of approvals, while the Southwest region showed the lowest growth rate [1] Future Directions - The State Administration for Market Regulation plans to enhance the supply of standard substances, focusing on emerging fields and promoting innovation in measurement technology within the manufacturing sector [1]

Group 1 - The core business of Beijing Bohui Innovation Biotechnology Group Co., Ltd. is the research, production, and sales of in vitro diagnostic products, including testing instruments, software, reagents, calibration products, quality control products, and national standard materials [1] - As of May 29, the company's stock closed at 5.93 yuan, with a 2.07% increase, a latest price-to-book ratio of 3.52, and a total market capitalization of 4.844 billion yuan [1] - The latest financial report for Q1 2025 shows the company achieved operating revenue of 202 million yuan, a year-on-year decrease of 23.05%, and a net profit of -4,054,437.18 yuan, a year-on-year decrease of 120.41%, with a gross profit margin of 38.37% [1] Group 2 - The company's price-to-earnings ratio (TTM) is -330.17, while the industry average is 49.64, indicating a significant underperformance compared to peers [2] - The company's market capitalization stands at 4.844 billion yuan, which is lower than the industry median of 4.928 billion yuan [2] - The company has a negative price-to-earnings ratio compared to other companies in the industry, such as Tianyi Medical and Aohua Endoscopy, which have ratios of -1776.29 and -644.66 respectively [2]